Chromosomal loci influencing the susceptibility to the Parkinsonian neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

Journal of Neuroscience

Volumn 23, Issue 23, 2003, Pages 8247-8253

  Sedelis, Marco ^a   Hofele, Katja ^b   Schwarting, Rainer K W ^c   Huston, Joseph P ^a   Belknap, John K ^d,e  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b NOVARTIS PHARMA AG   (Switzerland)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

Basal ganglia; Dopamine; F2 intercross; Inbred strains; Mouse; MPTP; Parkinson's disease; Quantitative trait loci

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE TRANSPORTER; NEUROTOXIN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHROMOSOME 13; CHROMOSOME 15; DOPAMINERGIC SYSTEM; ENVIRONMENTAL FACTOR; FEMALE; GENE LOCUS; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; MALE; MEMBRANE TRANSPORT; MOUSE; MOUSE STRAIN; NEOSTRIATUM; NERVE DEGENERATION; NEUROPATHOLOGY; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; QUANTITATIVE TRAIT LOCUS; SEX DIFFERENCE; STRIATONIGRAL DEGENERATION;

EID: 0141856492     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/jneurosci.23-23-08247.2003     Document Type: Article

References (53)

1. Arvin M, Fedorkova L, Disshon KA, Dluzen DE, Leipheimer RE (2000) Estrogen modulates responses of striatal dopamine neurons to MPP+: evaluations using in vitro and in vivo techniques. Brain Res 872:160-171.
2. Belknap JK, Mitchell SR, O'Toole LA, Helms ML, Crabbe JC (1996) Type I and type II error rates for quantitative trait loci (QTL) mapping studies using recombinant inbred mouse strains. Behav Genet 26:149-160.
3. Buck KJ, Metten P, Belknap JK, Crabbe JC (1997) Quantitative trait loci involved in genetic predisposition to acute alcohol withdrawal in mice. J Neurosci 17:3946-3955.
4. Chase K, Adler FR, Lark KG (1997) Epistat: a computer program for identifying and testing interactions between pairs of quantitative trait loci. Theor Appl Genet 94:724-730.
5. Checkoway H, Farin FM, Costa MP, Kirchner SC, Costa LG (1998) Genetic polymorphisms in Parkinson's disease. Neurotoxicology 19:635-643.
6. Churchill GA, Doerge RW (1994) Empirical threshold values for quantitative trait loci mapping. Genetics 138:963-971.
7. Crabbe JC, Phillips TJ, Buck KJ, Cunningham CL, Belknap JK (1999) Identifying genes for alcohol and drug sensitivity: recent progress and future directions. Trends Neurosci 22:173-179.
8. Dluzen DE, McDermott JL, Liu B (1996) Estrogen as a neuroprotectant against MPTP-induced neurotoxicity in C57/Bl mice. Neurotoxicol Teratol 18:603-606.
9. Feldman RG, Ratner MH (1999) The pathogenesis of neurodegenerative disease: neurotoxic mechanisms of action and genetics. Curr Opin Neurol 12:725-731.
10. Ferraro TN, Golden GT, Smith GG, Schork NJ, St.-Jean P, Ballas C, Choi H, Berrettini WH (1997) Mapping murine loci for seizure response to kainic acid. Mamm Genome 8:200-208.
11. Franklin KBJ, Paxinos G (1997) The mouse brain in stereotaxic coordinates. San Diego: Academic.
12. Freyaldenhoven TE, Ali SF (1997) Role of heat shock proteins in MPTP-induced neurotoxicity. Ann NY Acad Sci 825:167-178.
13. Freyaldenhoven TE, Ali SF, Hart RW (1995) MPTP- and MPP(+)-induced effects on body temperature exhibit age- and strain-dependence in mice. Brain Res 688:161-170.
14. Gainetdinov RR, Fumagalli F, Jones SR, Caron MG (1997) Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter. J Neurochem 69:1322-1325.
15. Gerlach M, Riederer P (1996) Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J Neural Transm 103:987-1041.
16. German DC, Nelson EL, Liang CL, Speciale SG, Sinton CM, Sonsalla PK (1996) The neurotoxin MPTP causes degeneration of specific nucleus A8, A9 and A10 dopaminergic neurons in the mouse. Neurodegeneration 5:299-312.
17. Giovanni A, Sieber BA, Heikkila RE, Sonsalla PK (1991) Correlation between the neostriatal content of the 1-methyl-4-phenylpyridinium species and dopaminergic neurotoxicity following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to several strains of mice. J Pharmacol Exp Ther 257:691-697.
18. Grünblatt E, Mandel S, Maor G, Youdim MBH (2001) Gene expression analysis in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice model of Parkinson's disease using cDNA microarray: effect of R-apomorphine. J Neurochem 78:1-12.
19. Hadley ME (1996) Endocrinology. Englewood Cliffs, NJ: Prentice-Hall.
20. Haley CS, Knott SA (1992) A simple regression method for mapping quantitative trait loci in line crosses using flanking markers. Heredity 69:315-324.
21. Hamre K, Tharp R, Poon K, Xiong XP, Smeyne RJ (1999) Differential strain susceptibility following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration acts in an autosomal dominant fashion: quantitative analysis in seven strains of Mus musculus. Brain Res 828:91-103.
22. Hofele K, Sedelis M, Auburger GW, Morgan S, Huston JP, Schwarting RKW (2001) Evidence for a dissociation between MPTP-toxicity and tyrosinase activity based on congenic mouse strain susceptibility. Exp Neurol 168:116-122.
23. Hood H, Belknap JK, Crabbe JC, Buck KJ (2001) Genome-wide search for epistasis in a complex trait: pentobarbital withdrawal convulsions in mice. Behav Genet 31:93-100.
24. Hoskins JA, Davis LJ (1989) The acute effect on levels of catecholamines and metabolites in brain, of a single dose of MPTP in 8 strains of mice. Neuropharmacology 28:1389-1397.
25. Hung HC, Lee EH (1996) The mesolimbic dopaminergic pathway is more resistant than the nigrostriatal dopaminergic pathway to MPTP and MPP+ toxicity: role of BDNF gene expression. Brain Res Mol Brain Res 41:14-26.
26. Jenner P (1998) Oxidative mechanisms in nigral cell death in Parkinson's disease. Mov Disord 13[Suppl 1]:24-34.
27. Johannessen JN, Adams JD, Schuller HM, Bacon JP, Markey SP (1986) 1-Methyl-4-phenylpyridine (MPP+) induces oxidative stress in the rodent. Life Sci 38:743-749.
28. Jones BC, Tarantino LM, Rodriguez LA, Reed CL, McClearn GE, Plomin R, Erwin VG (1999) Quantitative-trait loci analysis of cocaine-related behaviours and neurochemistry. Pharmacogenetics 9:607-617.
29. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392:605-608.
30. Lander ES, Kruglyak L (1995) Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results. Nat Genet 11:241-247.
31. Lincoln SE, Lander ES (1992) Systematic detection of errors in genetic linkage data. Genomics 14:604-610.
32. Manly KF, Olson JM (1999) Overview of QTL mapping software and introduction to Map Manager QT. Mamm Genome 10:327-334.
33. McNaught KS, Carrupt PA, Altomare C, Cellamare S, Carotti A, Testa B, Jenner P, Marsden CD (1998) Isoquinoline derivatives as endogenous neurotoxins in the aetiology of Parkinson's disease. Biochem Pharmacol 56:921-933.
34. Miller GW, Gainetdinov RR, Levey AI, Caron MG (1999) Dopamine transporters and neuronal injury. Trends Pharmacol Sci 20:424-429.
35. Mitsuhata C, Kitayama S, Morita K, Vandenbergh D, Uhl GR, Dohi T (1998) Tyrosine-533 of rat dopamine transporter: involvement in interactions with 1-methyl-4-phenylpyridinium and cocaine. Mol Brain Res 56:84-88.
36. Mizuno Y, Hattori N, Matsumine H (1998) Neurochemical and neurogenetic correlates of Parkinson's disease. J Neurochem 71:893-902.
37. Nicholl DJ, Bennett P, Hiller L, Bonifati V, Vanacore N, Fabbrini G, Marconi R, Colosimo C, Lamberti P, Stocchi F, Bonuccelli U, Vieregge P, Ramsden DB, Meco G, Williams AC (1999) A study of five candidate genes in Parkinson's disease and related neurodegenerative disorders. Neurology 53:1415-1421.
38. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276:2045-2047.
39. Przedborski S, Jackson-Lewis V, Djaldetti R, Liberatore G, Vila M, Vukosavic S, Almer G (2000) The parkinsonian toxin MPTP: action and mechanism. Restor Neurol Neurosci 16:135-142.
40. Rathke-Hartlieb S, Kahle PJ, Neumann M, Ozmen L, Haid S, Okochi M, Haas C, Schulz JB (2001) Sensitivity to MPTP is not increased in Parkinson's disease-associated mutant alpha-synuclein transgenic mice. J Neurochem 77:1181-1184.
41. Sanghera MK, Manaye K, McMahon A, Sonsalla PK, German DC (1997) Dopamine transporter mRNA levels are high in midbrain neurons vulnerable to MPTP. NeuroReport 8:3327-3331.
42. Schwarting R, Huston JP (1987) Short-term effects of ether, equithesin and droperidol/fentanyl on catecholamine and indolamine metabolism in the brain of the rat. Neuropharmacology 26:457-461.
43. Schwarting RKW, Huston JP (1996a) Unilateral 6-hydroxydopamine lesions of meso-striatal dopamine neurons and their physiological sequelae. Prog Neurobiol 49:215-266.
44. Schwarting RKW, Huston JP (1996b) The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery treatments. Prog Neurobiol 50:275-331.
45. Schwarting RKW, Sedelis M, Hofele K, Auburger GW, Huston JP (1999) Strain-dependent recovery of open-field behavior and striatal dopamine deficiency in the mouse MPTP model of Parkinson's disease. Neurotox Res 1:41-56.
46. Sedelis M, Hofele K, Auburger GW, Morgan S, Huston JP, Schwarting RKW (2000a) Evidence for resistance to MPTP in C57BL/6 × BALB/c F1 hybrids as compared with their progenitor strains. NeuroReport 11:1093-1096.
47. Sedelis M, Hofele K, Auburger GW, Morgan S, Huston JP, Schwarting RKW (2000b) MPTP susceptibility in the mouse: behavioral, neurochemical and histological analysis of gender and strain differences. Behav Genet 30:171-182.
48. Sedelis M, Schwarting RKW, Huston JP (2001) Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav Brain Res 125:109-125.
49. Sen S, Churchill GA (2001) A statistical framework for quantitative trait mapping. Genetics 159:371-387.
50. Son JH, Chun HS, Joh TH, Cho S, Conti B, Lee JW (1999) Neuroprotection and neuronal differentiation studies using substantia nigra dopaminergic cells derived from transgenic mouse embryos. J Neurosci 19:10-20.
51. Sundström E, Strömberg I, Tsutsumi T, Olson L, Jonsson G (1987) Studies on the effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in C57BL/6 mice. Comparison with three other strains of mice. Brain Res 405:26-38.
52. Tan EK, Khajavi M, Thornby JI, Nagamitsu S, Jankovic J, Ashizawa T (2000) Variability and validity of polymorphism association studies in Parkinson's disease. Neurology 55:533-538.
53. Uhl GR (1998) Hypothesis: the role of dopaminergic transporters in selective vulnerability of cells in Parkinson's disease. Ann Neurol 43:555-560.